Cantor Fitzgerald Issues Positive Outlook for Amgen Earnings

Amgen Inc. (NASDAQ:AMGN) – Research analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Amgen in a research report issued on Friday, May 2nd. Cantor Fitzgerald analyst C. Gould now expects that the medical research company will post earnings per share of $20.85 for the year, up from their prior forecast of $20.50. Cantor Fitzgerald has a “Neutral” rating and a $305.00 price objective on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $3.96 EPS.

Several other brokerages have also recently weighed in on AMGN. Royal Bank of Canada lowered their target price on Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a report on Friday. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday. Morgan Stanley reissued an “equal weight” rating on shares of Amgen in a research report on Friday. Piper Sandler upped their price target on shares of Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Finally, Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a research note on Wednesday, February 5th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and an average target price of $308.18.

Amgen Stock Down 0.9 %

Shares of NASDAQ AMGN opened at $281.22 on Monday. Amgen has a 52-week low of $253.30 and a 52-week high of $346.85. The firm has a market capitalization of $151.20 billion, a price-to-earnings ratio of 37.25, a PEG ratio of 2.63 and a beta of 0.51. The stock has a 50 day moving average price of $299.66 and a 200 day moving average price of $291.07. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David M. Reese sold 8,711 shares of Amgen stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the sale, the executive vice president now owns 62,147 shares of the company’s stock, valued at approximately $18,222,743.34. The trade was a 12.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 in the last ninety days. Company insiders own 0.69% of the company’s stock.

Institutional Investors Weigh In On Amgen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Centricity Wealth Management LLC acquired a new stake in Amgen during the fourth quarter valued at $25,000. Pinney & Scofield Inc. purchased a new stake in shares of Amgen during the 4th quarter worth about $26,000. First Pacific Financial grew its position in shares of Amgen by 304.5% during the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 67 shares during the period. Ritter Daniher Financial Advisory LLC DE increased its stake in shares of Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 51 shares in the last quarter. Finally, Synergy Investment Management LLC acquired a new position in Amgen in the 4th quarter worth about $34,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.